LTZ-301

**LTZ-301 is a first-in-class, bispecific myeloid engager antibody developed by LTZ Therapeutics. It is designed to selectively deplete CD79b-positive B-cells by enhancing antibody-dependent cellular phagocytosis (ADCP) through an Fc-gamma receptor-independent mechanism. The drug recruits and redirects monocytes and macrophages toward CD79b-positive B-cells, promoting phagocytosis and subsequent depletion of malignant B-cells. This approach targets B-cell malignancies, including those resistant or relapsed after CD19- or CD20-directed therapies. The initial clinical investigation focuses on patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL) who have exhausted standard treatment options. Preclinical studies demonstrated robust pharmacologic activity in both in vitro and in vivo models with a favorable safety profile.**[1][4][5]